Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Nanotechnology and Nano-Sized Tools: Newer Approaches to Circumvent Oncolytic Adenovirus Limitations Publisher Pubmed



Shirazi MMA1 ; Saedi TA2 ; Moghaddam ZS3 ; Nemati M4 ; Shiri R5 ; Negahdari B6 ; Goradel NH3, 7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Molecular Virology, Pasteur Institute of Iran, Tehran, Iran
  2. 2. Department of Genetics, Faculty of Science, Islamic Azad University, Tonekabon Branch, Tonekabon, Iran
  3. 3. Department of Medical Biotechnology, Maragheh University of Medical Sciences, Maragheh, Iran
  4. 4. Amir Oncology Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
  5. 5. Department of Basic Sciences, Maragheh University of Medical Sciences, Maragheh, Iran
  6. 6. Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Arthropod-Borne Diseases Research Centre, Ardabil University of Medical Sciences, Ardabil, Iran

Source: Pharmacology and Therapeutics Published:2024


Abstract

Oncolytic adenoviruses (OAds), engineered Ads preferentially infect and lyse tumor cells, have attracted remarkable attention as immunotherapy weapons for the treatment of various malignancies. Despite hopeful successes in preclinical investigations and translation into clinical phases, they face some challenges that thwart their therapeutic effectiveness, including low infectivity of cancer cells, liver sequestration, pre-existing neutralizing antibodies, physical barriers to the spread of Ads, and immunosuppressive TME. Nanotechnology and nano-sized tools provide several advantages to overcome these limitations of OAds. Nano-sized tools could improve the therapeutic efficacy of OAds by enhancing infectivity and cellular uptake, targeting and protecting from pre-existing immune responses, masking and preventing liver tropism, and co-delivery with other therapeutic agents. Herein, we reviewed the constructs of various OAds and their application in clinical trials, as well as the limitations they have faced. Furthermore, we emphasized the potential applications of nanotechnology to solve the constraints of OAds to improve their anti-tumor activities. © 2024